Back to top
more

Kite Pharma, Inc. (KITE)

(Delayed Data from NSDQ)

$179.79 USD

179.79
3,761,989

-0.02 (-0.01%)

Updated Oct 2, 2017 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sanghamitra Saha headshot

5 ETF Picks for October

by Sanghamitra Saha

A few ETF choices for the month of October.

    Ryan McQueeney headshot

    Here's Why Bluebird Bio (BLUE) Stock Is Falling Today

    by Ryan McQueeney

    Shares of Bluebird Bio (BLUE), a major player in the emerging gene therapy and CAR-T research markets, slumped more than 6% in morning trading Monday after receiving a key analyst downgrade.

      How Will Trump's Proposed Tax Reform Impact Drug Companies?

      by Zacks Equity Research

      Donald Trump has proposed new tax reforms for individuals and corporates. Let's see how the reforms, if passed, will impact pharma companies.

        Gilead (GILD) Gets Approval for HCV Drug Sovaldi in China

        by Zacks Equity Research

        Gilead Sciences' (GILD) blockbuster hepatitis C virus (HCV) infection drug, Sovaldi is now approved in China also.

          Kite Pharma Triples So Far in 2017: What's Driving the Rally?

          by Zacks Equity Research

          Kite Pharma's (KITE) shares have surged 300% so far this year riding on the progress of its CAR-T therapy candidate and a favorable buyout offer from Gilead.

            Gilead's (GILD) Epclusa Receives Label Expansion in Canada

            by Zacks Equity Research

            Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.

              Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval

              by Zacks Equity Research

              Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.

                3 Pharma/Biotech Sector Bargains for a Healthy Portfolio

                by Zacks Equity Research

                The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.

                  Implied Volatility Surging for Kite Pharma (KITE) Stock Options

                  by Zacks Equity Research

                  Investors need to pay close attention to Kite Pharma (KITE) stock based on the movements in the options market lately.

                    Ryan McQueeney headshot

                    Gilead Buys Kite, the Future of CAR-T, and A Visit to the New Whole Foods

                    by Ryan McQueeney

                    On today's episode of the Zacks Friday Finish Line, Content Writer Ryan McQueeney and Editor Maddy Johnson take on this week's biggest stories, including Gilead's acquisition of Kite Pharma, the future of the CAR-T therapy industry, and Amazon's changes to Whole Foods stores.

                      4 Biotech Stocks That More Than Doubled This Year

                      by Zacks Equity Research

                      The biotech sector has been witnessing an uptrend this year with impressive performance in both the quarters. Shares of quite a few companies have more than doubled so far this year riding this trend.

                        Sweta Killa headshot

                        5 Top Performing Stocks of the Top ETF of August

                        by Sweta Killa

                        Inside the top performing ETF of August and its top stocks.

                          Novartis (NVS) CAR-T Therapy Kymriah Receives FDA Approval

                          by Zacks Equity Research

                          Novartis AG (NVS) gets a major boost as the FDA approved its breakthrough gene transfer treatment, Kymriah for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL).

                            Ryan McQueeney headshot

                            Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap

                            by Ryan McQueeney

                            The cancer treatment industry is celebrating a massive victory on Wednesday, as Novartis (NVS) received approval for its innovative new lymphoblastic leukemia treatment, making it the first approved CAR-T therapy in the world.

                              Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal

                              by Zacks Equity Research

                              Gilead's (GILD) $11.8 billion deal to buy Kite Pharma KITE) has made two other leading independent CAR-T developers, Juno and Bluebird Bio hot takeover targets.

                                The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG

                                by Zacks Equity Research

                                The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG

                                  Kevin Cook headshot

                                  Indecision Won't Kill You, But It Will Take Your Money

                                  by Kevin Cook

                                  The pitfalls and powers of decision-making for traders and investors could be a model for everyone else.

                                    Gilead to Fly High with Kite Pharma Acquisition for $11.9B

                                    by Zacks Equity Research

                                    Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy.

                                      Ryan McQueeney headshot

                                      Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition

                                      by Ryan McQueeney

                                      Shares of Juno Therapeutics (JUNO) continued to soar on Tuesday. The stock has now gained nearly 40% since the announcement that fellow CAR-T cancer therapy designer Kite Pharma (KITE) is being acquired by biotech behemoth Gilead Sciences (GILD).

                                        Benjamin Rains headshot

                                        Why Did Kite Pharma (KITE) Stock Skyrocket Today?

                                        by Benjamin Rains

                                        Shares of cancer treatment drug maker Kite Pharma (KITE) soared on Monday morning after Gilead Sciences (GILD) officially announced it would purchase the company for a substantial premium.

                                          Kite Pharma at New 52-Week High: What's Driving the Stock?

                                          by Zacks Equity Research

                                          Kite Pharma (KITE) shares hit a new 52-week high as the company's CAR-T therapy with axicabtagene ciloleucel nears an FDA nod. It has also filed regulatory application for the candidate in the EU.

                                            Kite Pharma (KITE) Q2 Loss Narrower than Expected, Shares Up

                                            by Zacks Equity Research

                                            Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the second quarter of 2017 and beat estimates for sales. Shares of the biotech company rose 5.8% on Tuesday.

                                              Kite Pharma (KITE) Q2 Loss Narrower than Expected, Sales Beat

                                              by Zacks Equity Research

                                              Kite Pharma (KITE) reported narrower than expected loss in Q2 while sales beat expectations.

                                                Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More

                                                by Zacks Equity Research

                                                A look at the pharma/biotech companies that are set to report second-quarter results on Aug 8.

                                                  What's in the Cards for Kite Pharma (KITE) in Q2 Earnings

                                                  by Zacks Equity Research

                                                  With no approved products in its portfolio, investor focus will primarily be on Kite Pharma, Inc.'s (KITE) cash burn and pipeline updates.